Please select the option that best describes you:
Topics:
Sarcoma • Medical Oncology
What is your preferred systemic therapy for metastatic malignant peripheral nerve sheath tumor with early relapse after adjuvant AIM?
Given metastatic disease and not a trial candidate, how would you approach this scenario? How does an underlying diagnosis of NF1 affect your decision (if at all)?
Answer from: Medical Oncologist at Academic Institution
Persons with MPNST and NF-1 do worse than people without NF-1. I am suspicious that MPNST in persons without NF-1 is actually more than one entity but in NF-1 it is all the same entity.I have had some success with pazopanib in persons without NF-1. Also I have seen two persons who respon...
Sign in or Register to read more